Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Slides:

Advertisements

Similar presentations

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Pain in cancer survivors; filling in the gaps

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 144, Issue 2, Pages (February 2017)

Volume 147, Issue 1, Pages 3-10 (October 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 152, Issue 1, Pages (January 2019)

Volume 141, Issue 2, Pages (May 2016)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 148, Issue 1, Pages (January 2018)

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 3, Pages (September 2013)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 55, Pages S3-S16 (June 1999)

Characteristics of primary peritoneal serous carcinoma in a U. S

European Lung Cancer Conference (ELCC) 2016 Organisation

Volume 152, Issue 1, Pages (January 2019)

Table of Contents Nurse Leader Volume 16, Issue 3, (June 2018)

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Volume 154, Issue 2, Pages (August 2019)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne, J.Y. Chern, J. Lee, S.V. Blank Gynecologic Oncology Volume 141, (June 2016) DOI: 10.1016/j.ygyno.2016.04.085 Copyright © 2015 Terms and Conditions

Fig. 1 Percentage of Ovarian Cancer Survivors who Would Accept Treatment Side Effects based on the Goal of Treatment (cure vs. remission vs. disease). Gynecologic Oncology 2016 141, DOI: (10.1016/j.ygyno.2016.04.085) Copyright © 2015 Terms and Conditions